At CD BioSciences, we offer extensive preclinical safety and toxicology services to ensure the safety and efficacy of human herpesvirus (HHV) therapies in development. Our goal is to provide critical insights into the safety profiles of drug candidates, allowing you to make informed decisions as you move forward in the drug development process. Our services cater to HHV-focused therapies, with a specialized focus on both in vitro and in vivo assessments, including both non-GLP and GLP-compliant studies.
Our Services
- In Vitro Toxicology
In vitro toxicology testing is essential for understanding the initial safety profile of potential drug candidates. We offer a range of in vitro toxicology assays to assess cellular responses to HHV-targeted therapies.
General Cellular Cytotoxicity
We perform cytotoxicity assays, such as MTT and LDH assays, to determine the effects of a compound on cellular viability. This is a key assay for evaluating potential off-target effects and toxicity.
Off-Target Screening
We conduct off-target screening to identify potential risks associated with compound interactions outside the intended therapeutic target, with a focus on critical ion channels like hERG.
Organoid & 3D Tissue Model Toxicity Testing
We offer advanced 3D tissue model testing to evaluate toxicity in a more physiologically relevant system, which can provide better predictive data regarding drug candidate safety in human tissues.
- In Vivo Toxicology (Non-GLP & GLP-Compliant)
Our in vivo toxicology services are available in both non-GLP and GLP-compliant formats, offering flexibility based on your regulatory requirements. These studies are critical for assessing how a compound behaves in a whole organism.
Dose Range-Finding (DRF) & Maximum Tolerated Dose (MTD)
We determine the maximum tolerated dose to understand the safety thresholds of HHV-targeting therapies, providing valuable information on dosing regimens for future studies.
Single-Dose & Repeat-Dose Toxicity
Our services include single-dose and repeat-dose toxicity studies, which assess the long-term effects of a compound when administered over extended periods. This is crucial for identifying any cumulative toxicity risks associated with HHV-targeted therapies.
Safety Pharmacology (Core Battery: CNS, CV, Respiratory)
Our safety pharmacology studies are designed to evaluate potential risks to key physiological systems, including the central nervous system (CNS), cardiovascular (CV) system, and respiratory function. These studies are critical for understanding how a drug candidate may impact critical body systems.
Genetic Toxicology
Our genetic toxicology services, including the Ames test, micronucleus assay, and chromosomal aberration studies, are designed to identify any genetic mutations or DNA damage caused by drug candidates. This is an essential step in assessing mutagenic potential.
Immunotoxicology
Immunotoxicology studies help evaluate the potential for drug candidates to interfere with the immune system, which is especially important when developing therapies targeting viral infections such as HHV.
Why Choose CD BioSciences?
Our preclinical safety and toxicology services offer several advantages to clients in the HHV therapeutic space:
Expertise in HHV Therapies
With our specialized focus on HHV-related treatments, we bring unparalleled knowledge and expertise to the evaluation of antiviral drugs and vaccine candidates. Our team is experienced in understanding the specific challenges and risks associated with HHV therapies, including those aimed at targeting latency and reactivation.
Comprehensive and Flexible Services
We offer a full spectrum of toxicology services, both in vitro and in vivo, that can be tailored to meet your specific research needs. Whether you're advancing a drug candidate through early development or conducting final safety assessments, our services are designed to ensure you have the data needed to proceed with confidence.
Commitment to Quality and Compliance
Our services are compliant with industry regulations, including GLP standards, ensuring that our results are reliable and meet the expectations of regulatory bodies. Whether you are conducting exploratory research or preparing for clinical trials, our testing supports the rigorous safety requirements of the drug development process.
Cutting-Edge Technology
We utilize state-of-the-art techniques, such as 3D tissue models and advanced genetic assays, to provide more accurate and predictive toxicity data. Our technologies ensure that you can make informed decisions regarding the safety of your HHV-targeted therapies.
FAQs
Custom Reviews
Review 1:
"We've partnered with CD BioSciences for several preclinical studies, and their expertise in HHV therapies has been invaluable. Their toxicology services helped us identify critical safety data, which was essential for advancing our drug candidate to the next phase."
Review 2:
"CD BioSciences provided us with comprehensive safety testing for our HHV vaccine candidate. Their team's professionalism and advanced testing methodologies made a significant difference in our research outcomes."